George D. Yancopoulos - 06 Feb 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
President and Chief Scientific, Director
Signature
/s/**George D. Yancopoulos
Issuer symbol
REGN
Transactions as of
06 Feb 2023
Net transactions value
-$10,552,255
Form type
4
Filing time
08 Feb 2023, 15:15:24 UTC
Previous filing
23 Dec 2021
Next filing
27 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Sale $10,552,255 -13,189 -6.2% $800.08 200,504 06 Feb 2023 By Trust for Chldn. F1, F2, F3
holding REGN Common Stock 569,653 06 Feb 2023 Direct
holding REGN Common Stock 5,869 06 Feb 2023 By 401(k) Plan
holding REGN Common Stock 200,000 06 Feb 2023 by 2022 GRAT I
holding REGN Common Stock 250,000 06 Feb 2023 by 2022 GRAT II
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 Represents volume-weighted average price of sales of 13,189 shares of Company stock on February 6, 2023 at prices ranging from $800.00 to $800.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price.
F3 As investment trustee of trusts for the benefit of the reporting person's children.